Edition:
United Kingdom

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

8.32USD
13 Jul 2018
Change (% chg)

$-0.05 (-0.60%)
Prev Close
$8.37
Open
$8.35
Day's High
$8.39
Day's Low
$8.28
Volume
120,361
Avg. Vol
339,174
52-wk High
$9.11
52-wk Low
$4.61

Latest Key Developments (Source: Significant Developments)

Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement
Friday, 11 May 2018 

May 11 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT.PROGENICS PHARMA- CO,OTHER PLAINTIFFS ALLEGE PRODUCTS FOR WHICH PAR IS SEEKING U.S. MARKETING APPROVAL INFRINGES CO'S,OTHER PLAINTIFFS' U.S. PATENTS.  Full Article

Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA.PROGENICS PHARMACEUTICALS - ‍FDA GRANTED CO REQUEST FOR PRIORITY REVIEW; HAS SET ACTION DATE OF APRIL 30, 2018 UNDER PDUFA​.  Full Article

Progenics Pharmaceuticals Q3 loss per share $0.22
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - ‍Q3 revenue totaled $2.7 million, down from $53.9 million in Q3 of 2016​.Progenics - ‍ended Q3 with cash and cash equivalents of $98.3 million, decrease of $40.6 million versus cash and cash equivalents as of December 31, 2016​.  Full Article

Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®
Thursday, 30 Mar 2017 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra® . Progenics Pharmaceuticals Inc - study achieves primary endpoint . Progenics Pharmaceuticals Inc - secondary endpoint shows favorable tumor response to therapy .Progenics Pharmaceuticals Inc - company to submit nda in mid-2017.  Full Article

Progenics Pharmaceuticals Q2 loss per share $0.08
Thursday, 4 Aug 2016 

Progenics Pharmaceuticals Inc : Q2 loss per share $0.08 . Progenics Pharmaceuticals announces second quarter 2016 financial and business results . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S .On track to initiate phase 2/3 trial for PYL(TM) imaging agent and phase 1 trial for 1095 this year.  Full Article

BRIEF-Progenics Pharmaceuticals Announces Q1 Loss Per Share $0.19

* PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE